logo
Plus   Neg
Share
Email

Genome & Co. In Clinical Trial And Supply Deal With Merck KGaA, Pfizer

South Korea's Genome & Co. late Monday announced that it has entered into a clinical trial collaboration and supply agreement with Germany's Merck KGaA and US drug major Pfizer Inc.

The trial will evaluate the safety, tolerability, biological and clinical activities of GEN-001, Genome's microbiome-based immuno-oncology therapy, in combination with Merck KgaA and Pfizer's avelumab (BAVENCIO), a human anti-PD-L1 therapy, in multiple cancer indications.

Under the terms of the agreement, Genome & Co. will be the sponsor of the study. Merck KGaA and Pfizer will supply avelumab for the phase 1/1b clinical trial that is expected to be commenced in 2020 in the U.S. Both parties will have access to the clinical data.

The company expects to initiate the clinical trial in the coming months.

The combination trial is designed to be a first-in-human or FIH study including dose escalation and expansion cohorts to evaluate the safety and preliminary efficacy.

Avelumab in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced renal cell carcinoma or RCC.

Avelumab is currently approved for patients within 50 countries globally. Majority of these approvals are in a broad indication that is not limited to a specific line of treatment.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Safavieh LLC recalled about 760 units of Aura and Silas 3-Drawer Chests for possible serious tip-over and entrapment hazards that can result in death or injuries to children, the U.S. Consumer Product Safety Commission said in a statement. The company said the chests are unstable if they are not anchored to the wall. Shares of Standard Chartered Plc were losing around 4 percent in London trading after the bank warned on fiscal 2020 income growth mainly due to coronavirus impact. This was despite reporting a profit before tax in its fourth quarter, compared to last year's loss. For 2020, the company now expects income growth to be below its medium-term target range of 5 percent to 7 percent. A 2018 fatal crash involving a Tesla Inc. vehicle was likely caused by the car's autopilot system as well as distracted driving, according to a report by the National Transportation Safety Board or NTSB. The driver of the Tesla's Model X electric-powered sport utility vehicle, Walter Huang, was killed when it collided with a damaged crash attenuator on March 23, 2018 in Mountain View, California.
Follow RTT
>